Noam Barda

7.5k total citations · 4 hit papers
45 papers, 3.7k citations indexed

About

Noam Barda is a scholar working on Infectious Diseases, Health and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Noam Barda has authored 45 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Infectious Diseases, 8 papers in Health and 7 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Noam Barda's work include SARS-CoV-2 and COVID-19 Research (22 papers), COVID-19 Clinical Research Studies (13 papers) and Vaccine Coverage and Hesitancy (8 papers). Noam Barda is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (22 papers), COVID-19 Clinical Research Studies (13 papers) and Vaccine Coverage and Hesitancy (8 papers). Noam Barda collaborates with scholars based in Israel, United States and Italy. Noam Barda's co-authors include Ran D. Balicer, Noa Dagan, Ben Y. Reis, Marc Lipsitch, Miguel A. Hernán, Eldad Kepten, Oren Miron, Mark A. Katz, Isaac S. Kohane and Cyrille J. Cohen and has published in prestigious journals such as Science, New England Journal of Medicine and The Lancet.

In The Last Decade

Noam Barda

42 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

2021 1.6k citations Noa Dagan, Noam Barda et al. New England Journal of Medicine profile →
Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting

2021 672 citations Noam Barda, Noa Dagan et al. New England Journal of Medicine profile →
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study

2021 558 citations Noam Barda, Noa Dagan et al. profile →
Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy

2021 196 citations Noa Dagan, Noam Barda et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Noam Barda Israel	17	2.6k	1.1k	563	355	347	45	3.7k
Noa Dagan Israel	18	2.7k 1.0×	1.1k 1.0×	550 1.0×	326 0.9×	447 1.3×	37	4.0k
Sara E. Oliver United States	20	1.6k 0.6×	1.0k 0.9×	384 0.7×	117 0.3×	378 1.1×	54	2.9k
Bradley K. Ackerson United States	26	2.1k 0.8×	929 0.8×	396 0.7×	247 0.7×	222 0.6×	100	3.4k
Megan Wallace United States	19	1.4k 0.5×	936 0.8×	386 0.7×	93 0.3×	284 0.8×	41	2.5k
Tom T. Shimabukuro United States	37	2.5k 1.0×	1.6k 1.4×	209 0.4×	287 0.8×	873 2.5×	92	4.8k
John M. McLaughlin United States	29	2.3k 0.9×	1.3k 1.1×	726 1.3×	171 0.5×	173 0.5×	105	4.3k
Julianne Gee United States	32	1.9k 0.7×	1.9k 1.6×	216 0.4×	263 0.7×	865 2.5×	74	4.6k
Elise Tessier United Kingdom	15	2.4k 0.9×	1.2k 1.1×	829 1.5×	175 0.5×	79 0.2×	32	3.3k
Sharon Alroy‐Preis Israel	12	2.0k 0.8×	943 0.8×	617 1.1×	146 0.4×	69 0.2×	26	2.4k
Simon Thelwall United Kingdom	9	1.9k 0.7×	608 0.5×	581 1.0×	116 0.3×	126 0.4×	19	2.4k

Countries citing papers authored by Noam Barda

Since Specialization

Citations

This map shows the geographic impact of Noam Barda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Noam Barda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Noam Barda more than expected).

Fields of papers citing papers by Noam Barda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Noam Barda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Noam Barda. The network helps show where Noam Barda may publish in the future.

Co-authorship network of co-authors of Noam Barda

This figure shows the co-authorship network connecting the top 25 collaborators of Noam Barda. A scholar is included among the top collaborators of Noam Barda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Noam Barda. Noam Barda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Barda, Noam, et al.. (2025). Predicting antibody kinetics and duration of protection against SARS-CoV-2 following vaccination from sparse serological data. PLoS Computational Biology. 21(6). e1013192–e1013192.

Barda, Noam, Yaniv Lustig, Victoria Indenbaum, et al.. (2024). Risk factors and correlates of protection against XBB SARS-CoV-2 infection among health care workers. Vaccine. 42(26). 126308–126308. 4 indexed citations

Kern, Christoph, et al.. (2024). Bridging the gap: Towards an expanded toolkit for AI-driven decision-making in the public sector. Government Information Quarterly. 41(4). 101976–101976. 4 indexed citations

Lustig, Yaniv, Noam Barda, Victoria Indenbaum, et al.. (2024). Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and BA.5 mRNA COVID-19 vaccines. Vaccine. 42(22). 126010–126010. 2 indexed citations

Joseph, Gili, Ili Margalit, Carmit Rubin, et al.. (2024). Persistence of Long COVID Symptoms Two Years After SARS-CoV-2 Infection: A Prospective Longitudinal Cohort Study. Viruses. 16(12). 1955–1955. 4 indexed citations

Lustig, Yaniv, Victoria Indenbaum, Ili Margalit, et al.. (2024). SARS-CoV-2 IgG Levels as Predictors of XBB Variant Neutralization, Israel, 2022 and 2023. Emerging infectious diseases. 30(5). 1050–1052. 2 indexed citations

Barda, Noam, Eyal Klang, Paul Fefer, et al.. (2024). Enhancing Coronary Revascularization Decisions: The Promising Role of Large Language Models as a Decision-Support Tool for Multidisciplinary Heart Team. Circulation Cardiovascular Interventions. 17(11). e014201–e014201. 4 indexed citations

Miron, Oren, Noam Barda, Ran D. Balicer, Ariel Kor, & Shaul Lev‐Ran. (2022). Association of opioid use disorder with healthcare utilization and cost in a public health system. Addiction. 117(11). 2880–2886. 15 indexed citations

Hayek, Samah, Yatir Ben‐Shlomo, Eldad Kepten, et al.. (2022). Indirect protection of children from SARS-CoV-2 infection through parental vaccination. Science. 375(6585). 1155–1159. 34 indexed citations

10.

Barda, Noam, Mayan Gilboa, Keren Asraf, et al.. (2022). The Association Between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Clinical Infectious Diseases. 76(7). 1315–1317. 12 indexed citations

11.

Cohen-Stavi, Chandra J., Noam Barda, Shlomit Yaron, et al.. (2022). BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age. New England Journal of Medicine. 387(3). 227–236. 53 indexed citations

12.

Barda, Noam, Mayan Gilboa, Victoria Indenbaum, et al.. (2022). Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up. Nature Communications. 13(1). 7711–7711. 16 indexed citations

13.

Barda, Noam, Mayan Gilboa, Keren Asraf, et al.. (2022). Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022. Eurosurveillance. 27(39). 5 indexed citations

14.

Mittelman, Moshe, Noam Barda, Noa Dagan, et al.. (2021). Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting. Blood. 139(10). 1439–1451. 43 indexed citations

15.

Leader, Avi, Noa Dagan, Noam Barda, et al.. (2021). Previously undiagnosed cancer in patients with arterial thrombotic events – A population‐based cohort study. Journal of Thrombosis and Haemostasis. 20(3). 635–647. 7 indexed citations

16.

Dagan, Noa, Noam Barda, Eldad Kepten, et al.. (2021). BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. New England Journal of Medicine. 384(15). 1412–1423. 1619 indexed citations breakdown →

17.

Barda, Noam, Avshalom Leibowitz, Alexander Fardman, et al.. (2021). Myocardial injury in hospitalized patients with COVID-19 infection—Risk factors and outcomes. PLoS ONE. 16(2). e0247800–e0247800. 18 indexed citations

18.

Barda, Noam, Gal Yona, Guy N. Rothblum, et al.. (2020). Addressing bias in prediction models by improving subpopulation calibration. Journal of the American Medical Informatics Association. 28(3). 549–558. 40 indexed citations

19.

Dagan, Noa, Eldad Elnekave, Noam Barda, et al.. (2020). Automated opportunistic osteoporotic fracture risk assessment using computed tomography scans to aid in FRAX underutilization. Nature Medicine. 26(1). 77–82. 74 indexed citations

20.

Barda, Noam, Dan Riesel, Joseph Levy, et al.. (2020). Developing a COVID-19 mortality risk prediction model when individual-level data are not available. Nature Communications. 11(1). 4439–4439. 77 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact